SPOTLIGHT: ImClone pushes new indication
Following the successful conclusion of trials into Erbitux for head and neck cancer, ImClone says it will seek expanded use of the cancer drug in the third quarter. Erbitux is currently indicated for colorectal cancer. Story
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
